SCHEMBL25517072

SCHEMBL25517072

COC(=O)c1ccc2c(c1)C(=O)COC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.44
CA12 O43570 3/20 0.44
CA9 Q16790 3/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA14 Q9ULX7 2/20 0.44
XDH P47989 1/20 0.44
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ATM Q13315 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PTPRC P08575 1/20 0.42
CREBBP Q92793 1/20 0.41
PDK2 Q15119 1/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16499680 0.88 PTPRC (0.46) CASP3CA12CA9CA1CA2
SCHEMBL5503121 0.82 CA1 (0.50) CA12CA9CA1CA2CA7
SCHEMBL23715181 0.81 ALDH1A1 (0.49) CA12CA9CA1CA2ALDH1A1
SCHEMBL17385803 0.80 HSD17B1 (0.48) CASP3CA12CA9CA1CA2
SCHEMBL29446230 0.80 SMN1; SMN2 (0.50) CASP3CA12CA9CA1CA2
SCHEMBL354166 0.80 SMN1; SMN2 (0.50) CASP3CA12CA9CA1CA2
SCHEMBL11249792 0.80 MAPT (0.53) CASP3CA12CA9CA1CA2
SCHEMBL22898237 0.80 KDM4E (0.31) SMN1; SMN2KDM4ETDP1
SCHEMBL30688575 0.80 TSHR (0.41) ALDH1A1SMN1; SMN2PDK2KDM4EHSD17B10
SCHEMBL484748 0.80 PBRM1 (0.51) CASP3CA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CASP3 2649/4885CA12 4343/4885CA9 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.